

## Disclosure Results

**Imbruvica**

**European Marketing Authorisation Holder: Janssen-Cilag International NV**

phase	total complete by 31 July 2016	un-evaluable	evaluable	disclosed in 12 month timeframe	disclosed percentage at 12 months	complete by 31 July 2016	disclosed at 31 July 2016	disclosure percentage at 31st July 2016
phase I & II	14	4	10	10	100%	10	10	100%
phase III	5	1	4	4	100%	4	4	100%
phase IV	0	0	0	0		0	0	
other	0	0	0	0		0	0	
<b>total</b>	<b>19</b>	<b>5</b>	<b>14</b>	<b>14</b>	<b>100%</b>	<b>14</b>	<b>14</b>	<b>100%</b>

**Key to columns in table above:**

total complete by 31 July 2016 = total number of company-sponsored trials identified which were completed by 31 July 2016

unevaluable = trials with completion date within the last 12 months, or key dates missing - excluded from the analysis

evaluable = trials with all criteria present including dates; hence the base number of trials evaluated for the assessment

disclosed in 12 month timeframe = evaluable trials which were disclosed within the target 12 months\*

disclosed percentage at 12 months = proportion of evaluable trials which were disclosed within 12 months\*

complete before 31 July 2016 = number of evaluable trials completed before 31 July 2016

disclosed at 31 July 2016 = number of evaluable trials with results disclosed by 31 July 2016

disclosure percentage at 31 July 2016 = proportion of evaluable trials which were disclosed by 31 July 2016

[\* 12 months measured from the later of: the first date of regulatory approval (in Europe or the US) or the trial completion date]